These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
95 related articles for article (PubMed ID: 10517371)
21. Species-related inhibition of human and rat dihydroorotate dehydrogenase by immunosuppressive isoxazol and cinchoninic acid derivatives. Knecht W; Löffler M Biochem Pharmacol; 1998 Nov; 56(9):1259-64. PubMed ID: 9802339 [TBL] [Abstract][Full Text] [Related]
22. Assay of Escherichia coli dihydroorotase with enantiomeric substrate: practical preparation of carbamyl L-aspartate and high-performance liquid chromatography analysis of catalysis product. Daniel R; Kokel B; Caminade E; Martel A; Le Goffic F Anal Biochem; 1996 Aug; 239(2):130-5. PubMed ID: 8811890 [TBL] [Abstract][Full Text] [Related]
23. Suppression of experimental autoimmune neuritis by leflunomide. Korn T; Toyka K; Hartung HP; Jung S Brain; 2001 Sep; 124(Pt 9):1791-802. PubMed ID: 11522581 [TBL] [Abstract][Full Text] [Related]
24. Response of the pyrimidine pathway of Escherichia coli K 12 to exogenous adenine and uracil. Christopherson RI; Finch LR Eur J Biochem; 1978 Oct; 90(2):347-58. PubMed ID: 361403 [TBL] [Abstract][Full Text] [Related]
25. Anti-HIV-1 activity of leflunomide: a comparison with mycophenolic acid and hydroxyurea. Schläpfer E; Fischer M; Ott P; Speck RF AIDS; 2003 Jul; 17(11):1613-20. PubMed ID: 12853743 [TBL] [Abstract][Full Text] [Related]
26. Identification and characterization of potential new therapeutic targets in inflammatory and autoimmune diseases. Mangold U; Dax CI; Saar K; Schwab W; Kirschbaum B; Müllner S Eur J Biochem; 1999 Dec; 266(3):1184-91. PubMed ID: 10583416 [TBL] [Abstract][Full Text] [Related]
27. An overall radioassay for the first three reactions of de novo pyrimidine biosynthesis. Christopherson RI; Yu ML; Jones ME Anal Biochem; 1981 Mar; 111(2):240-9. PubMed ID: 6113788 [No Abstract] [Full Text] [Related]
28. Restriction of de novo pyrimidine biosynthesis inhibits Th1 cell activation and promotes Th2 cell differentiation. Dimitrova P; Skapenko A; Herrmann ML; Schleyerbach R; Kalden JR; Schulze-Koops H J Immunol; 2002 Sep; 169(6):3392-9. PubMed ID: 12218161 [TBL] [Abstract][Full Text] [Related]
29. Substitutions in the aspartate transcarbamoylase domain of hamster CAD disrupt oligomeric structure. Qiu Y; Davidson JN Proc Natl Acad Sci U S A; 2000 Jan; 97(1):97-102. PubMed ID: 10618377 [TBL] [Abstract][Full Text] [Related]
30. Uracil nucleotide synthesis in a human breast cancer cell line (MCF-7) and in two drug-resistant sublines that contain increased levels of enzymes of the de novo pyrimidine pathway. Karle JM; Cowan KH; Chisena CA; Cysyk RL Mol Pharmacol; 1986 Aug; 30(2):136-41. PubMed ID: 2874477 [TBL] [Abstract][Full Text] [Related]
31. Leflunomide: mode of action in the treatment of rheumatoid arthritis. Breedveld FC; Dayer JM Ann Rheum Dis; 2000 Nov; 59(11):841-9. PubMed ID: 11053058 [TBL] [Abstract][Full Text] [Related]
40. Mechanism of resistance of variants of the Lewis lung carcinoma to N-(phosphonacetyl)-L-aspartic acid. Kensler TW; Mutter G; Hankerson JG; Reck LJ; Harley C; Han N; Ardalan B; Cysyk RL; Johnson RK; Jayaram HN; Cooney DA Cancer Res; 1981 Mar; 41(3):894-904. PubMed ID: 7459875 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]